GL1X · GenesisL1 explorer

MolNFT v1 · #68973 · protein

Human macrophage inflammatory protein-1 alpha L3M_V63M

3KBX · CCL3: “Human macrophage inflammatory protein-1 alpha L3M_V63M”. X-ray diffraction, 1 ligand (K), 3 pockets (best druggability 0.63). MolNFT v1 #68973 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
3KBX
Type
protein
Length
330 residues
Chains
5
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
CCL3
UniProt
P10147
Ligands
K
Pockets
3 · best druggability 0.63

Structure

x-ray diffraction · 1 distinct chain · 21% helix, 23% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, C, D, ECCL3protein6621% helix, 23% strandP10147

Ligands and binding sites

  • K · Potassium ion · metal · chains A
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1520.630.9416empty
22190.600.8134empty
3880.420.7918empty

Interfaces

7 interfaces between chains.

  • D–E · 729 Ų buried · 11 hydrogen bonds · protein-protein
  • B–C · 712 Ų buried · 9 hydrogen bonds · protein-protein
  • A–B · 640 Ų buried · 7 hydrogen bonds · protein-protein
  • B–D · 630 Ų buried · 8 hydrogen bonds · protein-protein
  • C–E · 626 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 10 disulfide, 5 modified (disulfide, engineered).

Compared structures

  • 3KBX · Human macrophage inflammatory protein-1 alpha L3M_V63M · the same entry in another collection · chain E against E, TM-score 1.00
  • P10147 · AlphaFold monomer V2.0 prediction for C-C motif chemokine 3 (P10147) · a predicted model of the same protein · chain A against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.